<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509948</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CYT-07</org_study_id>
    <nct_id>NCT03509948</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation</brief_title>
  <official_title>A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, randomised, 2-treatment period, single-dose crossover study to
      determine the comparative bioavailability and renal elimination following single-dose
      administration of 3.0 mg cytisine in healthy smokers under fed and fasted conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Actual">June 12, 2018</completion_date>
  <primary_completion_date type="Actual">June 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing), up to 48 hours post-dose on Days 1-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-âˆž)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (T1/2)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time of Dosing to Last Measurable Concentration (AUC0-t)</measure>
    <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug</measure>
    <time_frame>Baseline (Day 0) through Day 5 plus 6-8 days</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of investigational product that worsen after the participant receives the first dose of investigational product. Relationship of the TEAE to study drug was evaluated as: definite, probably, possible, unlikely, or not related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values</measure>
    <time_frame>Screening through Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Schedule A: Fed Then Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schedule A (6 participants):
Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)
Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule B: Fasted Then Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schedule B (6 participants):
Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)
Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytisine</intervention_name>
    <description>cytisine 1.5 mg film-coated tablets</description>
    <arm_group_label>Schedule A: Fed Then Fasted</arm_group_label>
    <arm_group_label>Schedule B: Fasted Then Fed</arm_group_label>
    <other_name>Tabex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be Confirmed at Screening

          1. Subject is current cigarette smoker.

          2. Healthy males and females between 18 and 55 years of age.

               1. If a female subject of child bearing potential, a negative pregnancy test at
                  screening and admission and willing to use an effective method of contraception
                  (unless of non-childbearing potential or where abstaining from sexual intercourse
                  is in line with the preferred and usual lifestyle of the subject) from first dose
                  until 3 months after last dose of cytisine.

               2. If a female subject of non-child bearing potential, a negative pregnancy test at
                  screening and admission. For the purposes of this study, this is defined as the
                  subject being amenorrheic for at least 12 consecutive months or at least 4 months
                  post-surgical sterilisation (including bilateral fallopian tube ligation or
                  bilateral oophorectomy with or without hysterectomy). Menopausal status will be
                  confirmed by demonstrating at screening that levels of follicle stimulating
                  hormone (FSH) fall within the respective pathology reference range. In the event
                  a subject's menopause status has been clearly established (for example, the
                  subject indicates she has been amenorrheic for 10 years), but FSH levels are not
                  consistent with a post-menopausal condition, determination of subject eligibility
                  will be at Investigator's discretion following consultation with the Sponsor.

               3. If a male subject, willing to use an effective method of contraception (unless
                  anatomically sterile or where abstaining from sexual intercourse is in line with
                  the preferred and usual lifestyle of the subject) from first dose until 3 months
                  after last dose of cytisine.

          3. Subject with a body mass index (BMI) of 23-28 kg/m^2. BMI = body weight in kg /
             [height in m^2].

          4. Subject with no clinically significant abnormal serum biochemistry or haematology
             values within 28 days before the first dose of cytisine.

          5. Subject with negative urinary drugs of abuse screen, determined within 28 days before
             the first dose of cytisine (a positive result may be repeated at Investigator's
             discretion).

          6. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen
             (Hep B) and hepatitis C virus antibody (Hep C) results.

          7. Subject with no clinically significant abnormalities in 12-lead ECG determined after
             minimum of 5 minutes in supine position within 28 days before the first dose of
             cytisine.

          8. Subject with no clinically significant abnormalities in vital signs (systolic blood
             pressure between 90-140 mmHg, diastolic blood pressure (DBP) between 50 and 90 mmHg,
             and pulse rate (PR) between 40-100 bpm, measured on the dominant arm after minimum of
             5 minutes in supine position) determined within 28 days before first dose of cytisine.

          9. Subject must be available to complete the study (including post study follow-up) and
             comply with study restrictions.

         10. Subject must provide written informed consent to participate in the study.

        To be Re-Confirmed Prior to Dosing

          1. Subject continues to meet all screening inclusion criteria (before the cytisine dose).

          2. Subject has a negative urinary drugs of abuse screen (including alcohol).

          3. Female subject has a negative urine pregnancy test.

        Exclusion Criteria:

        To be Confirmed at Screening

          1. Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or
             any of the excipients in the Tabex formulation (cellulose, talc, magnesium).

          2. History of severe hypersensitivity reactions to any other drugs.

          3. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical
             condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics
             (absorption, distribution, metabolism or excretion).

          4. Female subjects who are breast feeding.

          5. Difficulty in donating blood on either arm or known history.

          6. History of alcoholism or drug abuse within last 2 years.

          7. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 14 days (or 5 half-lives, whichever is longer) prior to the
             cytisine dose, unless in the opinion of the Investigator the medication will not
             interfere with the study procedures or compromise subject safety.

          8. Participated in any investigational drug clinical trial within the previous 3 months
             or a marketed drug trial within the previous 30 days prior to randomization on Day 1
             of Period 1.

          9. Donation of 450 mL or more blood or had history of significant blood loss due to any
             reason or had plasmapheresis within 3 months before the cytisine dose.

         10. Any inability or difficulty in fasting.

         11. Inability to communicate well with Investigators (i.e., language problem, poor mental
             development or impaired cerebral function).

         12. Any other condition that the Principal Investigator considers making the subject
             unsuitable for this study.

        To be Re-Confirmed Prior to Dosing:

          1. Development of any exclusion criteria since screening.

          2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements since screening, unless in the opinion of the Investigator the medication
             will not interfere with the study procedures or compromise subject safety.

          3. Participation in a clinical study since the screening visit.

          4. Donation of 450 mL or more blood since the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezanul Abd Wahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research Ltd (Simbec)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Cardiff</city>
        <zip>CF11 9AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03509948/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03509948/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3 mg Cytisine, Schedule A: Fed Then Fasted</title>
          <description>Period 1: Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state).
Period 2: Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state).</description>
        </group>
        <group group_id="P2">
          <title>3 mg Cytisine, Schedule B: Fasted Then Fed</title>
          <description>Period 1: Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state).
Period 2: Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>3 mg Cytisine, Schedule A: Fed Then Fasted
Period 1: Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state).
Period 2: Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state).
3 mg Cytisine, Schedule B: Fasted Then Fed
Period 1: Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state).
Period 2: Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing), up to 48 hours post-dose on Days 1-5</time_frame>
        <population>Pharmacokinetic (PK) Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <population>Pharmacokinetic (PK) Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="37.2"/>
                    <measurement group_id="O2" value="32.9" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed/Fasted Ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric Least Squares Mean</param_type>
            <param_value>79.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.40</ci_lower_limit>
            <ci_upper_limit>95.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-âˆž)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-âˆž)</title>
          <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" spread="17.5"/>
                    <measurement group_id="O2" value="179" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed/Fasted Ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric Least Squares Mean</param_type>
            <param_value>92.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.37</ci_lower_limit>
            <ci_upper_limit>95.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>Urine Excretion Set: All participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)</title>
          <population>Urine Excretion Set: All participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="21.3"/>
                    <measurement group_id="O2" value="2.64" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed/Fasted Ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric Least Squares Mean</param_type>
            <param_value>90.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.99</ci_lower_limit>
            <ci_upper_limit>97.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>Urine Excretion Set: All participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)</title>
          <population>Urine Excretion Set: All participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>percent of cytisine excreted in urine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.60" spread="17.627"/>
                    <measurement group_id="O2" value="89.22" spread="13.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax)</title>
          <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O2" value="0.750" lower_limit="0.333" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed/Fasted Ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric Least Squares Mean</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (T1/2)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (T1/2)</title>
          <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="0.566"/>
                    <measurement group_id="O2" value="4.73" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Time of Dosing to Last Measurable Concentration (AUC0-t)</title>
        <time_frame>Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5</time_frame>
        <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time of Dosing to Last Measurable Concentration (AUC0-t)</title>
          <population>PK Set: All randomized participants who received both doses of cytisine and had sufficient, protocol-compliant plasma concentration-time profiles.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="17.2"/>
                    <measurement group_id="O2" value="173" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fed/Fasted Ratio</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Geometric Least Squares Mean</param_type>
            <param_value>91.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.55</ci_lower_limit>
            <ci_upper_limit>95.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of investigational product that worsen after the participant receives the first dose of investigational product. Relationship of the TEAE to study drug was evaluated as: definite, probably, possible, unlikely, or not related.</description>
        <time_frame>Baseline (Day 0) through Day 5 plus 6-8 days</time_frame>
        <population>Safety Set: All randomized participants who received at least 1 dose of cytisine.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an AE that: results in death; is life-threatening; requires hospitalization or prolongs existing inpatient hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes. TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of investigational product that worsen after the participant receives the first dose of investigational product. Relationship of the TEAE to study drug was evaluated as: definite, probably, possible, unlikely, or not related.</description>
          <population>Safety Set: All randomized participants who received at least 1 dose of cytisine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Relationship: Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Relationship: Not Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values</title>
        <time_frame>Screening through Day 5</time_frame>
        <population>Safety Set: All randomized participants who received at least 1 dose of cytisine.</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg Cytisine: Fed</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>3 mg Cytisine: Fasted</title>
            <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values</title>
          <population>Safety Set: All randomized participants who received at least 1 dose of cytisine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biochemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 0) through Day 5 plus 6-8 days</time_frame>
      <desc>TEAEs are presented</desc>
      <group_list>
        <group group_id="E1">
          <title>3 mg Cytisine: Fed</title>
          <description>Cytisine (2 x 1.5 mg tablets) administered 30 minutes after the start of a high fat breakfast (fed state)</description>
        </group>
        <group group_id="E2">
          <title>3 mg Cytisine: Fasted</title>
          <description>Cytisine (2 x 1.5 mg tablets) administered after an overnight fast of at least 10 hours (fasting state)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Cain, Vice President, Clinical Research</name_or_title>
      <organization>Achieve Life Sciences</organization>
      <phone>425.686.1546</phone>
      <email>dcain@achievelifesciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

